<DOC>
	<DOCNO>NCT02842827</DOCNO>
	<brief_summary>This Phase 1 open label study dose duration orally administer LSD1 inhibitor , IMG-7289 , patient acute myeloid leukemia ( AML ) myelodysplastic syndrome ( MDS ) . Some participant may also receive all-trans retinoic acid ( ATRA ; also know tretinoin VesanoidÂ® ) combination IMG-7289 . This study investigate follow : - The safety tolerability IMG-7289 , without ATRA - The pharmacodynamic effect different IMG-7289 dos treatment duration , well IMG-7289 administer combination ATRA - The pharmacokinetics IMG-2789 , without ATRA</brief_summary>
	<brief_title>IMG-7289 , With Without ATRA , Patients With Advanced Myeloid Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Tretinoin</mesh_term>
	<criteria>&gt; 18 year Diagnosis either AML ( subtypes exclude APLAML ) MDS World Health Criteria ( WHO ) High risk disease , define per protocol Receiving treatment condition ( exception time limit ) Major surgery last 4 week , minor surgery last 2 week Scheduled hematopoietic stemcell transplant Current use prohibit medication Clinical evidence central nervous system ( CNS ) pulmonary leukostasis , disseminate intravascular coagulation , CNS leukemia A concurrent second active nonstable malignancy Known HIV infection active Hepatitis B Hepatitis C virus infection Other hematologic/biochemistry requirement , per protocol Use investigational agent within last 14 day Pregnant lactating female</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>